The French Competition Authority fines three laboratories for abusive practices (Novartis / Roche / Genentech)

Treatment for AMD: the Autorité fines 3 laboratories for abusive practices* The Autorité de la concurrence has imposed fines worth a total of €444 million on three pharmaceutical companies, Novartis, Roche and Genentech, for abusive practices designed to sustain the sales of Lucentis for AMD treatment to the detriment of Avastin (a competitive medicinal product that is 30 times cheaper). Background Age-related macular degeneration (AMD) is the main cause of low vision for people over 50 in industrialized countries. It causes severe impairment of central vision, which is particularly present in the form of dark spots perceived by the patient in the middle of its vision. The Genentech laboratory has developed a drug, Lucentis, to treat AMD. It also developed another medicine, an

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

French Competition Authority, The French Competition Authority fines three laboratories for abusive practices (Novartis / Roche / Genentech), 9 septembre 2020, e-Competitions September 2020, Art. N° 96662

Visites 308

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues